- India launched a global study to evaluate Ayurveda as adjunct to TB treatment
- The study will enrol 1,250 new TB patients across eight institutions
- Focus areas include weight, nutrition, disease progress, quality of life, and safety
India on Tuesday launched a first-of-its-kind global clinical study to scientifically evaluate traditional Ayurveda as an adjunct to modern tuberculosis (TB) treatments. The study will enrol 1,250 newly diagnosed TB patients across eight institutions, focusing on body weight, nutritional outcomes, disease progression, quality of life, safety, and tolerability. Speaking at the launch of the study, Union Minister Jitendra Singh said, “Even after successful treatment, many TB patients continue to experience weakness, weight loss, and compromised quality of life, underlining the need for supportive and host-directed therapies.” He said India's rich heritage of Ayurveda offers unique opportunities for such interventions, particularly in improving nutrition, immunity and overall recovery. The minister also highlighted that India, which accounted for nearly 25 per cent of the global TB burden, registered a significant decline in incidence to around 187 cases per one lakh population in 2024, reflecting a 21 per cent reduction since 2015.
He said, “India has adopted an ambitious and accelerated pathway towards TB elimination, strengthening early diagnosis, universal drug susceptibility testing, digital adherence technologies, and patient-centric care under the National TB Elimination Programme.” The initiative has been developed under the Memorandum of Understanding (MoU) signed between the Ministry of Ayush and the Department of Biotechnology on May 25, 2022, and has progressed through consultations, protocol finalisation, and approvals.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
